ETFOptimize | High-performance ETF-based Investment Strategies

Quantitative strategies, Wall Street-caliber research, and insightful market analysis since 1998.


ETFOptimize | HOME
Close Window

Why DexCom (DXCM) Shares Are Sliding Today

DXCM Cover Image

What Happened?

Shares of medical device company DexCom (NASDAQ: DXCM) fell 2% in the morning session after Oppenheimer downgraded the stock to Perform from a previous Outperform rating. 

The investment firm cited growing competition concerns as the primary reason for the ratings change. In addition to the downgrade, Oppenheimer also removed its $102 price target for the medical device maker. An analyst downgrade typically signals a less optimistic outlook on a stock's future performance, which can lead investors to sell shares and put downward pressure on the price.

The stock market overreacts to news, and big price drops can present good opportunities to buy high-quality stocks. Is now the time to buy DexCom? Access our full analysis report here, it’s free.

What Is The Market Telling Us

DexCom’s shares are somewhat volatile and have had 14 moves greater than 5% over the last year. In that context, today’s move indicates the market considers this news meaningful but not something that would fundamentally change its perception of the business.

The previous big move we wrote about was 4 days ago when the stock gained 3.3% on the news that company executives provided an optimistic outlook at the Wells Fargo Healthcare Conference. During the conference, management expressed confidence in achieving "strong double-digit growth into the foreseeable future." The company also noted that a new product launch is "imminent." 

A key catalyst highlighted was the expansion of market access, with the third quarter being the first time all three major Pharmacy Benefit Managers (PBMs) will provide coverage for its non-insulin diabetes products. The company's leadership described this expanded coverage as a "real good opportunity," signaling a positive trajectory for future sales and market penetration.

DexCom is up 0.8% since the beginning of the year, but at $79.17 per share, it is still trading 12.8% below its 52-week high of $90.75 from February 2025. Investors who bought $1,000 worth of DexCom’s shares 5 years ago would now be looking at an investment worth $813.64.

Do you want to know what moves the business you care about? Add them to your StockStory watchlist and every time a stock significantly moves, we provide you with a timely explanation straight to your inbox. It’s free and will only take you a second.

Recent Quotes

View More
Symbol Price Change (%)
AMZN  241.56
+0.63 (0.26%)
AAPL  260.33
-2.03 (-0.77%)
AMD  210.02
-4.33 (-2.02%)
BAC  55.64
-1.61 (-2.81%)
GOOG  322.43
+7.88 (2.51%)
META  648.69
-11.93 (-1.81%)
MSFT  483.47
+4.96 (1.04%)
NVDA  189.11
+1.87 (1.00%)
ORCL  192.84
-0.91 (-0.47%)
TSLA  431.41
-1.55 (-0.36%)
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.


 

IntelligentValue Home
Close Window

DISCLAIMER

All content herein is issued solely for informational purposes and is not to be construed as an offer to sell or the solicitation of an offer to buy, nor should it be interpreted as a recommendation to buy, hold or sell (short or otherwise) any security.  All opinions, analyses, and information included herein are based on sources believed to be reliable, but no representation or warranty of any kind, expressed or implied, is made including but not limited to any representation or warranty concerning accuracy, completeness, correctness, timeliness or appropriateness. We undertake no obligation to update such opinions, analysis or information. You should independently verify all information contained on this website. Some information is based on analysis of past performance or hypothetical performance results, which have inherent limitations. We make no representation that any particular equity or strategy will or is likely to achieve profits or losses similar to those shown. Shareholders, employees, writers, contractors, and affiliates associated with ETFOptimize.com may have ownership positions in the securities that are mentioned. If you are not sure if ETFs, algorithmic investing, or a particular investment is right for you, you are urged to consult with a Registered Investment Advisor (RIA). Neither this website nor anyone associated with producing its content are Registered Investment Advisors, and no attempt is made herein to substitute for personalized, professional investment advice. Neither ETFOptimize.com, Global Alpha Investments, Inc., nor its employees, service providers, associates, or affiliates are responsible for any investment losses you may incur as a result of using the information provided herein. Remember that past investment returns may not be indicative of future returns.

Copyright © 1998-2017 ETFOptimize.com, a publication of Optimized Investments, Inc. All rights reserved.